Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2018, Article ID 4708068, 3 pages
https://doi.org/10.1155/2018/4708068
Case Report

Colonic Mucosal Ulceration and Gastrointestinal Bleeding Associated with Sevelamer Crystal Deposition in a Patient with End Stage Renal Disease

1Pulmonary & Critical Care Medicine, Cancer Treatment Centers of America, Tulsa, OK, USA
2Nephrology, Indiana University, Muncie, IN, USA
3Pulmonary Critical Care Medicine, University of Missouri, Columbia, MO, USA
4USD Sanford School of Medicine, Vermillion, SD, USA
5Hematology and Oncology, Cancer Treatment Centers of America, Tulsa, OK, USA

Correspondence should be addressed to Sudheer Nambiar; moc.liamg@ykraibman

Received 21 November 2017; Revised 15 January 2018; Accepted 24 January 2018; Published 28 February 2018

Academic Editor: Yoshihide Fujigaki

Copyright © 2018 Sudheer Nambiar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Cannata-Andía, J. L. Fernández-Martín, F. Locatelli et al., “Use of phosphate-binding agents is associated with a lower risk of mortality,” Kidney International, vol. 84, no. 5, pp. 998–1008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Shanahan, M. H. Crouthamel, A. Kapustin, and C. M. Giachelli, “Arterial calcification in chronic kidney disease: key roles for calcium and phosphate,” Circulation Research, vol. 109, no. 6, pp. 697–711, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Floege, “Phosphate binders in chronic kidney disease: a systematic review of recent data,” Journal of Nephrology, vol. 29, no. 3, pp. 329–340, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, “KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),” Kidney International Supplements, vol. 76, pp. S1–S130, 2009. View at Publisher · View at Google Scholar
  5. UptoDate, 2007, http://utdol.com/utd/content/topic.do?topicKey=drug_l_z/78586&selectedTitle=1~14&source=search_result.
  6. P. Madan, S. Bhayana, P. Chandra, and J. I. Hughes, “Lower gastrointestinal bleeding: Association with Sevelamer use,” World Journal of Gastroenterology, vol. 14, no. 16, pp. 2615-2616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Yuste, E. Mérida, E. Hernández et al., “Gastrointestinal complications induced by sevelamer crystals,” Clinical Kidney Journal, vol. 10, no. 4, pp. 539–544, 2017. View at Publisher · View at Google Scholar
  8. B. J. Swanson, B. N. Limketkai, T. C. Liu et al., “Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury,” American Journal of Pathology, vol. 37, no. 11, pp. 1686–1693, 2013. View at Google Scholar